2018–2019 Drug Updates in Hematologic Malignancies

Lauren Held, PharmD, BCOP, updated attendees on the FDA-approved therapies for initial or expanded indications for hematologic malignancies across the past year, as well as their supporting clinical trial data and best practices for safe and effective dosing and administration, drug monitoring, and...

Descripción completa

Detalles Bibliográficos
Autor principal: Held, Lauren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2020
Materias:
Meeting Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857325/
https://www.ncbi.nlm.nih.gov/pubmed/33598320
http://dx.doi.org/10.6004/jadpro.2020.11.3.7
Descripción
Sumario:Lauren Held, PharmD, BCOP, updated attendees on the FDA-approved therapies for initial or expanded indications for hematologic malignancies across the past year, as well as their supporting clinical trial data and best practices for safe and effective dosing and administration, drug monitoring, and adverse event management.

Ejemplares similares